Skip to Content

ASCO 2025: Groundbreaking Data in Bladder and Prostate Cancers

The American Society of Clinical Oncology (ASCO) 2025 meeting is set to unveil groundbreaking research in urothelial and prostate cancers. Key topics will include potential targets for antibody-drug conjugates (ADCs), resistance mechanisms, novel combination therapies, and their clinical applications in advanced bladder cancer. 

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top